Ulacamten

Small molecule

Also known as CK-4021586

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Heart Failure with Preserved Ejection Fraction
Phase 1 (1)
Other / comorbidity
NCT05877053 · Cytokinetics
2023-05-09 – 2024-11-20 · Healthy Participants
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Heart Failure with Preserved Ejection Fraction: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ulacamten: this drugPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Aficamten (Myqorzo)
Approved(overall)
Small moleculeCardiac myosin (inhibitor)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Mavacamten (Camzyos)
Approved(overall)
Small moleculeCardiac myosin (inhibitor)
Reliable signal(overall)
No reviewed efficacy summary in this indication
HRS-1893
Phase 3(overall)
UndisclosedCardiac myosin (inhibitor)
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (Wegovy)Phase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.